Drugs / ACLIMOSTAT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03254368 | Sep 2017 → Nov 2018 | type 2 diabetes mellitus | Zafgen, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACLIMOSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297651 ↗ |
| Known as | ZGN-1061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03254368 ↗ |
| Action | Inhibit | “ZGN-1061 is a methionine aminopeptidase 2 inhibitor” NCT03254368 ↗1“Methionine aminopeptidase 2 inhibitor” CHEMBL4297651 ↗ |
| Modality | Small molecule | — CHEMBL4297651 ↗ |
| Route | Subcutaneous | “0.05 mg ZGN-1061 subcutaneous injection once every 3 days” NCT03254368 ↗ |
| Target | METAP2 | “Methionine aminopeptidase 2 inhibitor” CHEMBL4297651 ↗ |